Fort Lauderdale, FL, August 26, 2015 - OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, and Seoul National University Hospital Clinical Trials Center (SNUH CTC), a leading academic medical center in the Republic of Korea, announced the go-live of TrialOne the global leader in eSource and Early Phase clinic automation.
TrialOne was selected by SNUH CTC after an extensive market evaluation to automate its early phase study activities. The successful implementation will allow SNUH CTC to streamline their clinical trial processes by supporting more efficient work flows while delivering a substantial increase in the data quality and reducing the timelines of their clinical trials and related services to their clients.
“We are very delighted that OmniComm’s TrialOne has been successfully incorporated into the SNUH’s early clinical trial environment. This will dramatically increase the quality, efficiency, and speed of our research activities from subject recruitment to data management,” stated Professor Yung-Jue Bang, MD, PhD, president of the Biomedical Research Institute, SNUH, and director of SNUH CTC.
SNUH implemented TrialOne in a semi-phased approach starting with TrialOne Recruitment. This phase included a Korean database migration successfully managed by OmniComm Professional Services. Shortly thereafter, the remainder of the TrialOne suite was implemented including electronic data collection, direct data capture from devices, data and query management and sample tracking. SNUH is the first TrialOne site in Asia to go live with the full TrialOne suite.
This 52 bed Early Phase clinic and its 50 TrialOne users are anticipating at least thirty studies annually. Their first TrialOne study was a multiple dose study with data captured in both English and Korean.
“The Clinical Trials Center of Seoul National University Hospital belongs to the absolute top of clinical research institutes in East Asia. For OmniComm, the successful implementation of TrialOne at SNUH CTC is an important step in our further advancement into the Asian market,” says Wolf Ondracek, senior vice president academic and Asian markets, OmniComm Systems.
Commenting on the successful implementation, Randy Smith, chairman and CTO, OmniComm Systems, said, “This success was only possible through a strong partnership with Seoul National University Hospital, having the right team in place from both Seoul National University Hospital and OmniComm, and a strong commitment to deliver and set up Seoul National University Hospital for success. The TrialOne solution provides the platform to allow Seoul National University Hospital to execute on its strategic plan for the long term.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Obe-Cel Achieves High Response Rates, Durable Outcomes in r/r B-Cell Acute Lymphoblastic Leukemia
December 3rd 2024CAR T-cell therapy obecabtagene autoleucel produced high response rates, durable outcomes, and low toxicity in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, especially benefiting those with low-to-intermediate bone marrow burden.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Opdivo plus Yervoy Significantly Outperforms Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer
December 2nd 2024Phase III CheckMate 8HW trial results demonstrated that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improves progression-free survival and has a better safety profile compared to chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.